Background. ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)-hyperintense tumor assessed by central reading prognosticate overall survival (OS). Methods. Two hundred eighty-four patients (171 men; median age 57 y, range 19-79; 159 on bevacizumab) had MRI at post-op (baseline) and pre-cycle 4 of adjuvant temozolomide (22 wk post chemoradiation initiation). Four central readers measured bidimensional lesion enhancement (2D-T1) and FLAIR hyperintensity at both time points. Changes from baseline to pre-cycle 4 for both markers were dichotomized (increasing vs non-increasing). Cox proportional hazards model and Kaplan-Meier survival estimates were used for inference. Results. Adjusting for treatment, increasing 2D-T1 (n = 262, hazard ratio [HR] = 2.07, 95% CI: 1.48-2.91, P < 0.0001) and FLAIR (n = 273, HR = 1.75, 95% CI: 1.26-2.41, P = 0.0008) significantly predicted worse OS. Median OS (days) was significantly shorter for patients with increasing versus non-increasing 2D-T1 for both bevacizumab (443 vs 535, P = 0.004) and placebo (526 vs 887, P = 0.001). Median OS was significantly shorter for patients with increasing versus non-increasing FLAIR for placebo (595 vs 872, P = 0.001), and trended similarly for bevacizumab (499 vs 535, P = 0.0935). Adjusting for 2D-T1 and treatment, increasing FLAIR represented significantly higher risk for death (HR = 1.59 [1.11-2.26], P = 0.01). Conclusion. Increased 2D-T1 significantly predicts worse OS in both treatment groups, implying absence of a substantial proportion of pseudoprogression 22 weeks after initiation of standard therapy. FLAIR adds value beyond 2D-T1 in predicting OS, potentially addressing the pseudoresponse effect by substratifying bevacizumab-treated patients with non-increasing 2D-T1.
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NeuroOncology
Glioblastoma, the most common and aggressive primary brain tumor, has a dismal prognosis, with median survival of 14-16 months 1 and 5-year survival rate of 9.8%. 2 Surgical resection followed by chemoradiation with concomitant and adjuvant temozolomide (TMZ) is the standard of care, offering prolonged overall survival (OS), 3 but progressive glioblastoma is uniformly fatal, with median survival under 30 weeks. 4 Glioblastoma stem cells promote tumor angiogenesis, 5 prompting use of anti-angiogenic drugs in clinical treatment trials. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, 6 is FDA approved for second-line treatment of recurrent glioblastoma, 7 appearing to confer a clinical benefit in early phase II clinical trials 8 compared with historic controls. 3 However, not all recurrent glioblastomas respond to bevacizumab, and "response" in this setting is poorly defined. 9 Radiologic markers providing early indication of treatment failure for standard and anti-angiogenic therapy and timely opportunity to select alternative treatments or trials are therefore important.
However, posttreatment image interpretation is challenging because of 2 confounders. 10 Pseudoprogression is transient increased contrast enhancement mimicking tumor progression 11 that commonly follows radiotherapy and TMZ within 1-6 months 12 and stabilizes or resolves without further intervention, potentially conferring improved survival. 13, 14 Its mechanism likely involves pro-inflammatory mediators and cytokines 15 producing edema and contrast enhancement that are difficult to distinguish from progressive disease on conventional MRI, 16 prompting modification of response assessment criteria to allow for the possibility of pseudoprogression within 12 weeks, and possibly up to 6 months after completion of radiation. 17 Pseudoresponse reflects decreased contrast enhancement independent of antitumor effect, typically in the setting of anti-angiogenic therapy. Bevacizumab yields high response rates and prolonged progressionfree survival (PFS) without improved OS, 1 illustrating how pseudoresponse limits early response assessment and motivating the inclusion of non-enhancing tumor (fluid attenuated inversion recovery [FLAIR] ) in response assessment criteria. 17 The ability of changes in contrast enhancement and FLAIR to predict OS is therefore uncertain and controversial.
Radiation Therapy Oncology Group (RTOG) 0825, a multicenter randomized phase III trial of conventional concurrent chemoradiation and adjuvant TMZ with or without bevacizumab in newly diagnosed glioblastoma, provided the opportunity to evaluate posttreatment conventional MRI metrics for predicting OS using controlled, retrospective central reader methodology. ACRIN 6686 is the companion study that evolved to investigate the association between changes in tumor size measured by postcontrast T1-weighted or FLAIR images prior to cycle 4 of adjuvant TMZ and OS in both treatment arms. Specifically, we analyzed the RTOG 0825 image set to determine: (i) the relationship between OS and change in tumor size on contrast-enhanced T1-weighted and FLAIR images; (ii) the ability of change in enhancement and FLAIR to independently prognosticate OS in each treatment arm with attention to possible pseudoprogression and pseudoresponse; and (iii) the added value of FLAIR beyond contrast-enhanced T1 in prognosticating OS and distinguishing pseudoresponse from true response for bevacizumab therapy.
Materials and Methods
RTOG, in collaboration with the American College of Radiology Imaging Network (ACRIN), both funded by the National Cancer Institute, conducted a prospective phase III double-blind placebo-controlled multicenter trial comparing conventional concurrent chemoradiation and adjuvant TMZ without versus with bevacizumab in patients with newly diagnosed glioblastoma (RTOG 0825/ACRIN 6686). Each participating institution obtained institutional review board approval before subject accrual and conducted the trial with Health Insurance Portability and Accountability Act compliance. Informed consent was obtained for all subjects.
Study Subjects and Treatment
All patients had newly diagnosed, histologically proven glioblastoma or gliosarcoma (World Health Organization grade IV astrocytoma) confirmed on central review. Detailed inclusion and exclusion criteria are available at https://www.acrin.org/Portals/0/Protocols/6686/Protocol-RTOG0825-ACRIN6686_Amend4_12. 16 .10_ForOnline.pdf
Importance of the study
This study establishes that changes in tumor enhancement and FLAIR from baseline to pre-cycle 4 of adjuvant temozolomide are prognostic imaging markers for OS. Increased enhancement at pre-cycle 4 in patients on standard therapy was strongly associated with poor OS, implying absence of substantial pseudoprogression at this time (22 wk following treatment initiation) and helping define the period during which pseudoprogression must be considered using Response Assessment in Neuro-Oncology (RANO) criteria. FLAIR had independent prognostic value for OS, and added value beyond 2D-T1 in predicting OS, supporting its inclusion in RANO. On the basis of a 0% threshold for progression (increasing vs non-increasing), FLAIR further substratified bevacizumab-treated patients with improving contrast enhancement, addressing the issue of pseudoresponse and helping to further refine T1-based OS assessment for standard therapy. Because literature results vary greatly for alternative FLAIR thresholds, our results suggest that FLAIR thresholds must be judiciously selected for RANO.
(Section 3.0). Fractionated, conformal radiotherapy or intensity-modulated radiotherapy (2 Gy/d, 5 d/wk for 6 wk) was delivered to the postoperative cavity, marginating enhancement, and surrounding FLAIR signal abnormality plus a 2 cm margin (46 Gy in 23 fractions, followed by a boost of 14 Gy in 7 fractions). Temozolomide treatment (75 mg/m 2 p.o. daily) coincided with radiotherapy (maximum of 49 doses). Patients were randomly assigned to receive standard therapy plus bevacizumab or standard therapy alone (referred to as the placebo arm); stratification factors included methylation status of O 6 -methylguanine-DNA methyl-transferase and a 9-gene tumor-based molecular profile. Bevacizumab (for the bevacizumab arm) was administered (10 mg/kg i.v., days 1 and 15 of a 28-d cycle) starting at week 4 of radiotherapy, until disease progression, severe treatment-related toxicity, or completion of adjuvant therapy (24 doses over 12 cycles, maximum). Maintenance TMZ began 4 weeks after completion of radiotherapy (150 mg/m 2 p.o. for 5 consecutive days of a 28-day cycle, increased to 200 mg/m 2 p.o. for subsequent cycles in the absence of treatment-related adverse events of grade 2 or higher). 1 
Imaging Timeline
MRI exams occurred at postoperative baseline; approximately 4 weeks after completion of radiotherapy prior to cycle 1 of maintenance TMZ; prior to cycle 4 of maintenance TMZ (typically occurring 22 wk following initiation of chemoradiation, and referred to herein as the "pre-cycle 4" time point); and before initiation of cycles 7 and 10 of maintenance TMZ, if administered. Patients completing adjuvant treatment had follow-up MRIs every 3 months until tumor progression.
MRI Protocol
Conventional MRI included precontrast T1-weighted, T2-weighted, FLAIR, and diffusion-weighted imaging. After intravenous injection of 0.1 mmol/kg of standard gadolinium-based contrast agent, axial 2D spin-echo postcontrast T1-weighted images (herein referred to as "2D-T1" for simplicity) with or without 3D volumetric T1-weighted images were acquired. Patients participating in the optional advanced component of the trial (ACRIN 6686, to be reported separately) also had dynamic contrast-enhanced and/or dynamic susceptibility contrast perfusion-weighted MRI at up to 4 additional time points: 0-5 days pre-chemoradiation, 0-3 days pre-bevacizumab/ placebo cycle 1, 0-1 day post-bevacizumab/placebo cycle 1 initiation, and post-chemoradiation. The complete MRI protocol is documented online at https://www.acrin.org/ Portals/0/Protocols/6686/Protocol-RTOG0825-ACRIN6686_ Amend4_12.16.10_ForOnline.pdf (Appendix XII).
Central Reader Methods
All local imaging was transmitted to ACRIN for central review. Four primary readers, each with neuroradiology certificates of added qualification and 26, 14, 10, and 8 years of post-fellowship experience, were trained at ACRIN headquarters regarding 2D measurement techniques. Each primary reader, blinded to clinical outcome data, then conducted independent image assessments remotely using XenApp (Citrix Systems) desktop virtualization software. Image analysis in 2D was performed using MIM analysis software. For each distinct contrastenhancing target lesion (≥1 cm diameter, ≥1 cm from other enhancing lesions), the largest diameter of contrast enhancement and its maximum co-planar perpendicular diameter were measured on the spin-echo postcontrast T1-weighted images following RANO guidelines, 17 with similar measurements made on corresponding FLAIR images. Readers were instructed to identify tumor-related FLAIR hyperintensity, although it is acknowledged that objective tumor-related FLAIR measures are difficult to prescribe. 17 Tumor areas in 2D-T1 and FLAIR were computed by summing over all lesions the product of maximum perpendicular diameters. Pre-and postcontrast images were reviewed simultaneously to exclude blood products from 2D areas.
Two standard imaging exams were evaluated for each patient: the baseline postoperative MRI and the MRI performed before cycle 4 of adjuvant TMZ (pre-cycle 4). For all evaluable patients with imaging available at both time points, one (190 patients) or two (94 patients) central readers independently made 2D-T1 and FLAIR measurements. For patients evaluated by 2 central readers, the measurements from 1 reader were randomly selected for statistical analysis.
Study Cohort
Six hundred twenty-one patients were randomized in RTOG 0825 and included in the main study publication. 1 Of those, patients were discounted who lacked baseline imaging (n = 16), pre-cycle 4 imaging (n = 206, including 98 who died before pre-cycle 4), or complete and interpretable 2D-T1 or FLAIR datasets at baseline and pre-cycle 4 (n = 48), or for whom pre-cycle 4 MRI fell outside the week 20-28 range (n = 67), leaving 284 analyzable datasets (2D-T1 and/or FLAIR) with post-op baseline and pre-cycle 4 imaging. There were 148 and 114 interpretable 2D-T1 datasets for the bevacizumab and placebo arms, respectively (262 total). There were 153 and 120 interpretable FLAIR datasets for the bevacizumab and placebo arms, respectively (273 total).
Statistical Methods
Hazard ratio (HR) from the multivariate Cox proportional hazards model with or without treatment and marker interaction terms was used to detect the association between changes in 2D-T1 and FLAIR imaging markers and OS. Kaplan-Meier survival curves and log-rank tests were used to compare OS between patients with increasing versus non-increasing markers. All tests were 2-sided with significance level of 0.05 and were performed using SAS 9.4.
The Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP) of the National Cancer Institute supported image processing and statistical analysis.
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Eastern Cooperative Oncology Group-ACRIN and NRG Oncology approved the manuscript prior to submission. (Fig. 2) . For both the patients on bevacizumab (HR = 1.92, 95% CI: 1.22-3.02, P = 0.0049) and placebo (HR = 2.33, 95% CI: 1.39-3.92, P = 0.0014), increasing 2D-T1 was strongly associated with 
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worse survival (Table 2 ). These findings suggest that there is no substantial pseudoprogression effect at pre-cycle 4 (typically 22 wk after initiation of chemoradiation). (Table 2 and Fig. 3 ).
Subgroup Analysis of the Relationship Between Change in FLAIR and OS
Multivariate Modeling of the Additive Value of FLAIR for Predicting OS
Of the 254 patients with both 2D-T1 and FLAIR measurements, 40 had increased 2D-T1 and FLAIR from baseline to pre-cycle 4, 143 had decreased 2D-T1 and FLAIR, and 71 had increased value for one but not both. In a multivariate Cox regression model including 2D-T1, FLAIR, and treatment variables, increased FLAIR represented a 59% higher risk for death (HR = 1.59, 95% CI: 1.11-2.26, P = 0.01) when adjusting for 2D-T1 change and treatment. There were no statistically significant interactions between 2D-T1, FLAIR, and treatment in the multivariate model, suggesting that this association between FLAIR and survival is independent of treatment assignment and change in 2D-T1. For bevacizumab therapy, FLAIR may help distinguish pseudoresponders from true responders. In Fig. 4A , patients with non-increasing 2D-T1 (black survival curve in Fig. 2A) 
NeuroOncology
further refine 2D-T1-based prognostication of OS for standard therapy illustrated in Fig. 2B. In Fig. 4B , patients with non-increasing 2D-T1 (black survival curve in Fig. 2B 
Discussion
Pseudoprogression is a common 18 local inflammatory reaction 15 following radiotherapy and TMZ, marked by progressive enhancement and subsequent radiologic improvement or stabilization without modified therapy. 11, 12, 19 The modified RANO criteria recognize the possibility of pseudoprogression within 6 months (60% of the time within 3 mo) after completion of chemoradiation. 12, 14, [19] [20] [21] Precycle 4 MRI typically occurred approximately 22 weeks after initiation of chemoradiation (16 weeks after completion of chemoradiation). There was strong correlation of 2D-T1 with OS in the standard therapy arm at pre-cycle 4 ( Fig. 2B) , implying the absence of a strong pseudoprogression effect. This suggests that progressive enhancement beyond 16 weeks post-chemoradiation is likely to be real, placing an upper bound on the time frame during which pseudoprogression should be considered in RANO. Assuming similar absence of pseudoprogression at precycle 4 in the bevacizumab arm, the strong correlation between increased 2D-T1 and OS ( Fig. 2A) demonstrates that worsened enhancement implicates true tumor progression and a failure of treatment to inhibit tumor growth. These findings recapitulate results for recurrent glioblastoma from ACRIN 6677, a phase II trial of bevacizumab with or without irinotecan in recurrent glioblastoma, reaffirming the significance of progressive enhancement in glioblastomas on anti-angiogenic therapy. 22 Pseudoresponse occurs with anti-angiogenic agents like bevacizumab that reduce contrast agent extravasation and discernible tumor enhancement independent of cytotoxic or cytostatic effect, 23 thereby limiting early response assessment 10 and prompting inclusion of non-enhancing tumor in modified response assessment criteria. 17 FLAIR hyperintensity may progress after anti-angiogenic therapy despite decreased tumor-related contrast enhancement, 24 explaining why enhancement-based response may be incongruous with and a poor predictor of OS. 25 RTOG 0825 illustrated this concept. For 637 newly diagnosed glioblastomas, OS did not differ significantly between patients on bevacizumab and placebo, despite significantly longer PFS, as primarily assessed by imaging, in the bevacizumab group. 1 Furthermore, bevacizumab has been shown to reduce imaging changes associated with radiation-related necrosis 26 and thus will likely reduce the incidence of pseudoprogression. Therefore, a lower incidence of pseudoprogression on the bevacizumab arm likely contributed to the discordance between the PFS and OS results for the trial.
FLAIR was added to the RANO criteria in order to identify non-enhancing tumor progression, particularly for anti-angiogenic therapies. 27 Retrospective analysis found that FLAIR helps identify progression approximately one month earlier than contrast enhancement alone, but without significant differences in predicted OS. 28 Use of FLAIR has been controversial due to the subjective nature of its interpretation, as evidenced by the dependence of OS prediction upon nuances of FLAIR segmentation, including demarcation of circumscribed versus infiltrative patterns. 29 The utility of FLAIR also depends upon the threshold used for declaring progression, which is not specified by RANO. For instance, Huang evaluated recurrent glioblastomas from the AVF3708g trial and found that RANO inclusion of subjective FLAIR progression yielded statistically significant differences in median PFS and objective response rate compared with Macdonald criteria, although objective response rate and PFS determined by both RANO and Macdonald criteria correlated with OS. 28 Radbruch also found that addition of FLAIR to RANO increases the sensitivity for glioblastoma progression, with a 15% threshold for FLAIR progression having far superior performance to a 25% threshold. 30 Concordantly, for recurrent glioblastomas in ACRIN 6677, a 25% threshold for FLAIR progression was not helpful for substratifying by OS the 2D-T1 nonprogressors at 8 or 16 weeks after bevacizumab initiation. 22 In our study that uses a 0% threshold, OS differed significantly between patients with increasing versus non-increasing FLAIR for the placebo arm, and increasing FLAIR was strongly associated with worse survival. We observed similar trends in the bevacizumab arm for differences in median survival and association with worse survival (Fig. 3) . Therefore, the additive value of FLAIR appears to depend strongly upon the criteria for declaring FLAIR progression, which must seemingly be carefully defined before FLAIR can provide consistent benefit in response assessment. 31 Our results confirm the presence of pseudoresponse in the bevacizumab arm at pre-cycle 4 and demonstrate that FLAIR may help distinguish true responders from pseudoresponders. Of the patients with non-increasing 2D-T1, the subgroup with increasing FLAIR had significantly shorter survival than the subgroup with non-increasing FLAIR, with median survival not significantly different than that for patients with increasing 2D-T1 (Fig. 4A) . These results imply the presence of pseudoresponse, with an artifactual absence of worsened 2D-T1 in the setting of worsened FLAIR-delineated tumor burden. Substratification by FLAIR of 2D-T1 non-increasers in this study differs from the findings in ACRIN 6677, 22 where for the 2D-T1 nonprogressors, there was no statistically significant OS reduction among FLAIR progressors compared with nonprogressors at 8 and 16 weeks after bevacizumab initiation. An important difference between these studies, in addition to the timing interval between bevacizumab initiation and imaging, is the selected FLAIR thresholds. Whereas ACRIN 6677 required a 25% increase in FLAIR for progression, for this study we imposed a 0% threshold. A threshold for lesion progression on FLAIR is not quantified by RANO, and our results support previous evidence that lower thresholds are more sensitive for isolated FLAIR progression. 30 In the standard therapy arm, our results analogously show that FLAIR may help further refine 2D-T1-based prognostication of OS. Of the patients with non-increasing 2D-T1, the subgroup with increasing FLAIR had survival more similar to that for patients with increasing 2D-T1 than patients with non-increasing FLAIR (Fig. 4B) , further emphasizing the importance of FLAIR when prognosticating survival based on 2D-T1 for standard therapy.
Although OS is the standard endpoint for glioblastoma therapy trials, it may not be suitable when high crossover rates exist in the control arm. For instance, a large percentage of patients in the placebo arms for RTOG 0825 (48%) and AVAglio (31%), another phase III study of bevacizumab efficacy, eventually received bevacizumab. 1, 32 There is therefore interest in determining whether 6-month PFS (PFS6), for instance, is a meaningful surrogate for OS in clinical trials. 33 Of the prescribed imaging time points in RTOG 0825, pre-cycle 4, typically occurring 22 weeks after initiation of chemoradiation, was closest to the 6-month time point without exceeding it. We therefore used precycle 4 to determine the relationship between OS and PFS6 based on 2D-T1 and FLAIR, using a 0% threshold for progression. Adjusting for treatment, both increasing 2D-T1 and FLAIR were significantly associated with worse survival (Fig. 1) . Therefore, analogous to conventional measures of PFS in other trials, [33] [34] [35] simple measures of change for these markers approximately 6 months after initiation of chemoradiation were highly predictive of OS. Furthermore, adjusting for treatment across all patients, every unit of additive difference in 2D-T1 or FLAIR between baseline and pre-cycle 4 corresponded to a significant increased risk of death, establishing 2D-T1 and FLAIR as predictive imaging markers for survival. Use of PFS has challenges, including measurement variability and discordance in interpretation between radiologists, 36 although a 0% threshold is simple and may reduce discrepancies due to scaling biases.
When assessing the relationship between tumor growth and OS, we dichotomized patients based upon increasing versus non-increasing 2D-T1 or FLAIR at pre-cycle 4 compared with baseline. This essentially uses a 0% threshold for progression, compared with the 25% threshold for 2D-T1 progression imposed by the Macdonald and RANO criteria. The Macdonald and RANO thresholds defining response and progression are arbitrary without scientific basis for optimized correlation with OS or PFS. Thresholds based on percentage change with respect to baseline tumor size are greatly biased toward diminutive tumors where relatively small changes in tumor size yield large percentage changes. 37 This is particularly relevant for newly diagnosed glioblastomas, where either small initial tumors or those with minimal residual postoperative enhancement often progress early when non-measurable disease reaches the measurable threshold or small growth produces substantial percentage change in size. Among our 94 patients evaluated by 2 readers, the kappa statistic for classification as increasing versus non-increasing on 2D-T1 was 0.60 (88 patients), and 0.64 on FLAIR (92 patients), both at the boundary between moderate and substantial agreement. In ACRIN 6677, the adjudication rate for 2 central readers identifying time of progression (25% threshold) was approximately 40% (39%, FLAIR; 43%, 2D-T1). 22 These results illustrate the challenges associated with reproducible implementation of response assessment criteria.
Volumetric response evaluation has been theorized to improve the RANO criteria. 31 We used conventional 2D bidirectional measures of contrast-enhancing tumor, as specified currently by RANO, and similarly used 2D measures of FLAIR. Central readers also made 3D segmentations of enhancement and FLAIR, with qualitatively similar performance of 2D and 3D measures of enhancement and FLAIR (results not shown). Bidirectional measurements may overestimate tumor volume 38 and yield higher reader discordance. 39 However, several studies 37, 40 have demonstrated concordance between 2D-T1 and 3D-T1 methods for determining radiologic response of newly diagnosed and recurrent high-grade gliomas, including ACRIN 6677 22 and the recently published BELOB trial for recurrent glioblastoma, where volumetric methods did not significantly improve upon RANO for prognosis. 41 Bidirectional assessment may provide a quicker, more practical alternative to volumetric segmentation, although given the geometric complexity of contrast enhancement and FLAIR hyperintensity in treated glioblastomas, volumetric segmentations facilitated by 3D-T1 difference maps obtained with a newly standardized brain tumor imaging protocol 42 may ultimately improve accuracy, and computerization of such measures may lessen interobserver variability. 43 Other modifications to the RANO criteria have been proposed 31 that differ from the methodology of our study. Contrast-enhanced T1-weighted subtraction maps increase lesion conspicuity 44 but are facilitated by acquisition of pre-and postcontrast volumetric T1-weighted images using identical pulse sequence parameters (for example, as prescribed by a consensus brain tumor imaging protocol 42 ) but not included in ACRIN 6686. Use of the postradiation time point as baseline for response assessment has also been proposed. The first posttherapy MRI prescribed in ACRIN 6686 was at pre-cycle 1 (4 wk after completion of initial chemoradiation), and to maintain consistency with the methodology of prior investigations, as well as the original aims of the BIQSFP grant funding this trial, we used the postoperative, pretherapy scan as baseline.
According to the World Health Organization 2016 diagnostic criteria, glioblastoma is not a formally complete diagnosis, and is further classified by isocitrate dehydrogenase (IDH) mutation status. The parent RTOG 0825 trial pre-dated this classification, and IDH mutational data are unavailable. It is likely that our cohort contains both IDH wildtype and mutant patients. However, 219/284 (77%) patients in our cohort were at least 50 years old (in proportion to RTOG 0825), a cohort that should be nearly completely wildtype. It is therefore likely that our results are generally applicable to IDH-wildtype glioblastomas.
In conclusion, changes in tumor enhancement and FLAIR from baseline to pre-cycle 4 of adjuvant TMZ are prognostic imaging markers for OS. Increased enhancement at pre-cycle 4 in patients on standard therapy is strongly associated with poor OS, implying absence of substantial pseudoprogression at this time (approximately 22 wk after NeuroOncology treatment initiation) and helping define the period when pseudoprogression must be considered using RANO criteria. Similar results in the bevacizumab arm recapitulate the findings from ACRIN 6677. 22 FLAIR has independent prognostic value for OS overall, and added value beyond 2D-T1 in predicting OS. For bevacizumab therapies, FLAIR can substratify T1 non-increasers (helping to identify pseudoresponse), and for standard therapy, FLAIR may help further refine T1-based OS assessment.
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